{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:53:55Z","timestamp":1781920435371,"version":"3.54.5"},"reference-count":50,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thrombin generation assays (TGA) provide a dynamic and integrative assessment of thrombin generation in clotting plasma ex vivo. The method is characterized by triggering coagulation, typically via the extrinsic pathway, and continuously measuring thrombin activity using a fluorogenic peptide substrate to derive key parameters such as peak thrombin and the endogenous thrombin potential. Several assay platforms are currently available, with the original Calibrated Automated Thrombogram (CAT) still being widely used in clinical and research settings, not least due to its flexibility and ability to analyze both platelet-poor as well as platelet-rich plasma. Thrombin generation assays have the potential to support the evaluation and monitoring of treatment of bleeding disorders, including hemophilia A and B and other inherited or acquired coagulation factor deficiencies. They may contribute to risk stratification in thrombotic disorders, and support the assessment of anticoagulant therapies. However, besides ongoing developments and optimization of trigger reagents, inter-assay variability and susceptibility to pre- and analytical variables challenge assay standardization and inter-laboratory comparability. Continued refinement, harmonization, and prospective clinical validation will be essential to unlock the full diagnostic potential of TGA.<\/jats:p>","DOI":"10.1055\/a-2753-9825","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T23:30:27Z","timestamp":1771371027000},"page":"065-070","source":"Crossref","is-referenced-by-count":3,"title":["Thrombin Generation Assays: Possibilities and Limitations"],"prefix":"10.1055","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3424","authenticated-orcid":false,"given":"Behnaz","family":"Pezeshkpoor","sequence":"additional","affiliation":[{"name":"Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/labmed\/lmx050","article-title":"Coagulation testing in the core laboratory","volume":"48","author":"W E Winter","year":"2017","journal-title":"Lab Med"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/a-1153-5824","article-title":"Can we measure the individual prothrombotic or prohemorrhagic tendency by global coagulation tests?","volume":"40","author":"S Reda","year":"2020","journal-title":"Hamostaseologie"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"F Depasse","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1111\/jth.15538","article-title":"Clinical use of thrombin generation assays","volume":"19","author":"N B Binder","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/jth.14863","article-title":"Towards standardization of thrombin generation assays: inventory of thrombin generation methods based on results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey","volume":"18","author":"R MW de Laat-Kremers","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"M Ninivaggi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s44313-024-00040-8","article-title":"Back to basics: the coagulation pathway","volume":"59","author":"S Park","year":"2024","journal-title":"Blood Res"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1378\/chest.124.3_suppl.26S","article-title":"The protein C pathway","volume":"124","author":"C T Esmon","year":"2003","journal-title":"Chest"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1160\/TH13-10-0811","article-title":"Natural inhibitors of thrombin","volume":"111","author":"J A Huntington","year":"2014","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.rpth.2022.100018","article-title":"Thrombin generation and implications for hemophilia therapies: a narrative review","volume":"7","author":"R F Sidonio Jr","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability","volume":"32","author":"H C Hemker","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/rth2.12048","article-title":"A review of commercially available thrombin generation assays","volume":"2","author":"J Kintigh","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12959-023-00549-5","article-title":"Sources of bias and limitations of thrombinography: inner filter effect and substrate depletion at the edge of failure algorithm","volume":"21","author":"J W Jackson","year":"2023","journal-title":"Thromb J"},{"issue":"01","key":"ref14","first-page":"35","article-title":"Multicenter analytical performance evaluation of the ST Genesia thrombin generation system","volume":"83","author":"L Talon","year":"2025","journal-title":"Ann Biol Clin (Paris)"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"K J Pasi","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"ref16","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"A D Shapiro","year":"2019","journal-title":"Blood"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.18420","article-title":"A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia","volume":"200","author":"J N Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"109045","DOI":"10.1016\/j.thromres.2024.109045","article-title":"Comparative analysis of thrombin generation platforms for patients with coagulation factor deficiencies: a comprehensive assessment","volume":"240","author":"B Haisma","year":"2024","journal-title":"Thromb Res"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1160\/TH08-10-0670","article-title":"Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?","volume":"101","author":"H M Spronk","year":"2009","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1538-7836.2004.00964.x","article-title":"Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition","volume":"2","author":"R Luddington","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.thromres.2014.04.010","article-title":"Evaluation of pre-analytical variables in a commercial thrombin generation assay","volume":"134","author":"S E Rodgers","year":"2014","journal-title":"Thromb Res"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"e0263960","DOI":"10.1371\/journal.pone.0263960","article-title":"The influence of corn trypsin inhibitor on the contribution of coagulation determinants to the Technoclone Thrombin Generation Assay (TGA) and the Calibrated Automated Thrombogram (CAT)","volume":"17","author":"C E Touw","year":"2022","journal-title":"PLoS One"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/jth.12659","article-title":"Failure of corn trypsin inhibitor to affect the thrombin generation assay in plasma from severe hemophiliacs","volume":"12","author":"B M Mohammed","year":"2014","journal-title":"J Thromb Haemost"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1033416","DOI":"10.3389\/fcvm.2022.1033416","article-title":"Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases","volume":"9","author":"L LFG Valke","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/JBM.S342077","article-title":"Acquired haemophilia A: a review of what we know","volume":"13","author":"M E Mingot-Castellano","year":"2022","journal-title":"J Blood Med"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/a-2651-8816","article-title":"Usefulness of global coagulation tests, thrombin generation and viscoelastic tests for assessing the bleeding phenotype in rare coagulation factor deficiencies","volume":"45","author":"T Dreier","year":"2025","journal-title":"Hamostaseologie"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/ijlh.14406","article-title":"Thrombin generation assay to support hematologists in the era of new hemophilia therapies","volume":"47","author":"L Josset","year":"2025","journal-title":"Int J Lab Hematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1055\/a-2687-0107","article-title":"Laboratory monitoring in patients receiving emicizumab","author":"J M\u00fcller","year":"2025","journal-title":"Hamostaseologie"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"102658","DOI":"10.1016\/j.rpth.2024.102658","article-title":"No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy","volume":"9","author":"K van der Zwet","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/hae.70108","article-title":"Utilising thrombin generation assay to guide co-administration of factor therapies with fitusiran","volume":"31","author":"Y Dargaud","year":"2025","journal-title":"Haemophilia"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"103180","DOI":"10.1016\/j.rpth.2025.103180","article-title":"Marstacimab, an antitissue factor pathway inhibitor, combined with bypassing agents: effects on thrombin generation and in hemostatically normal rats","volume":"9","author":"M A Peraza","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"09","key":"ref32","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jtha.2024.05.033","article-title":"Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study","volume":"22","author":"J Dubut","year":"2024","journal-title":"J Thromb Haemost"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"109384","DOI":"10.1016\/j.thromres.2025.109384","article-title":"Thrombin generation assay in venous thromboembolism: a scoping review","volume":"252","author":"M EM Souza","year":"2025","journal-title":"Thromb Res"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"e0146922","DOI":"10.1371\/journal.pone.0146922","article-title":"Genetic determinants of thrombin generation and their relation to venous thrombosis: results from the GAIT-2 Project","volume":"11","author":"L Martin-Fernandez","year":"2016","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1075121","DOI":"10.3389\/fcvm.2023.1075121","article-title":"Application of the thrombin generation assay in patients with antiphospholipid syndrome: a systematic review of the literature","volume":"10","author":"R Gehlen","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.thromres.2022.10.007","article-title":"Thrombin generation assay as a biomarker of cardiovascular outcomes and mortality: a narrative review","volume":"220","author":"L GR Ferreira","year":"2022","journal-title":"Thromb Res"},{"issue":"15","key":"ref37","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study","volume":"29","author":"C Ay","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"ref38","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.3390\/diagnostics14222553","article-title":"Comparative investigation of thromboelastometry and thrombin generation for patients receiving direct oral anticoagulants or vitamin K antagonists","volume":"14","author":"A Tripodi","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays\u2014a review of the literature","volume":"21","author":"J R Shaw","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jtha.2023.03.011","article-title":"Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII","volume":"21","author":"B Pezeshkpoor","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"16734","DOI":"10.1038\/s41598-023-43941-x","article-title":"Comparison of antithrombin activity assays in detection of patients with heparin binding site antithrombin deficiency: systematic review and meta-analysis","volume":"13","author":"T Rojnik","year":"2023","journal-title":"Sci Rep"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1160\/TH09-03-0180","article-title":"Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram","volume":"102","author":"K R Machlus","year":"2009","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/ijlh.13388","article-title":"Biological variation data and analytical specification goal estimates of the thrombin generation assay with and without thrombomodulin in healthy individuals","volume":"43","author":"A Mairesse","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"07","key":"ref44","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/jth.15736","article-title":"Antithrombotic potential of a single-domain antibody enhancing the activated protein C-cofactor activity of protein S","volume":"20","author":"J C Sedzro","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"102271","DOI":"10.1016\/j.rpth.2023.102271","article-title":"NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V","volume":"8","author":"Y Nakajima","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jth.13134","article-title":"Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive","volume":"13","author":"E K Waters","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MBC.0000000000000898","article-title":"Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients","volume":"31","author":"I V Gribkova","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","article-title":"A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X","volume":"112","author":"K Ogiwara","year":"2020","journal-title":"Int J Hematol"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1055\/a-2101-7961","article-title":"Sensitive measurement of clinically relevant factor VIII levels in thrombin generation assays requires presence of factor XIa","volume":"123","author":"T W van de Berg","year":"2023","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref50","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1538-7836.2009.03488.x","article-title":"Biological variation in inflammatory and hemostatic markers","volume":"7","author":"G Rudez","year":"2009","journal-title":"J Thromb Haemost"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2753-9825.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T23:31:31Z","timestamp":1771371091000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2753-9825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2753-9825","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}